Clara, person with Parkinson's and origami hobbyist Making everyday life significantly better for people affected by neurological diseases May, 10 2021 © 2021 Adamas Pharmaceuticals, Inc. | All Rights Reserved. Confidential and Proprietary. Forward looking statements 2 › Statements contained in this presentation regarding matters that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements c ...

Clara, person with Parkinson's and origami hobbyist Making everyday life significantly better for people affected by neurological diseases May, 10 2021 © 2021 Adamas Pharmaceuticals, Inc. | All Rights Reserved. Confidential and Proprietary. Forward looking statements 2 › Statements contained in this presentation regarding matters that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements c ...

Adamas Pharmaceuticals, Inc. (ADMS) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Neil McFarlane – Chief Executive Officer Vijay Shreedhar – Chief Commercial Officer Chris Prentiss – Chief Financial Officer Adrian Quartel – Chief Medical Officer Conference Call Participants Marc Goodman – SVB Leerink Lachlan Hanbury-Brown – William Blair Jason Butler – JMP Securities Stacy Ku – Cowen & Co. Zack Sachar – Piper Sandler Operator Welcome to the Ad ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 20 ...

| --- | --- | |------------------------------------------------------------------------------------------|-------| | | | | | | | Supernus Pharmaceuticals | | | © 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. Corporate Overview April 2021 | | Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Sup ...

Clara, person with Parkinson's and origami hobbyist Making everyday life significantly better for people affected by neurological diseases MARCH 2, 2021 © 2021 Adamas Pharmaceuticals, Inc. | All Rights Reserved. Confidential and Proprietary. Forward looking statements 2 › Statements contained in this presentation regarding matters that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2020 or ☐ TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 20-2590184 | | ...

| --- | --- | |------------------------------------------------------------|-------| | | | | | | | Supernus Pharmaceuticals Corporate Overview February 2021 | | | © 2021 Supernus Pharmaceuticals, Inc. All Rights Reserved. | | Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus' business strategy, g ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Peter Vozzo - Westwicke Partners Jack Khattar - Founder, President, CEO, Secretary & Director James Kelly - EVP & CFO Conference Call Participants David Steinberg - Jefferies David Amsellem - Piper Sandler & Co. Nicholas Rubino - Stifel, Nicolaus & Company Operator Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2020 Financial Results Conference ...

Clara, person with Parkinson's and origami hobbyist Making everyday life significantly better for people affected by neurological diseases FEBRUARY 23, 2021 © 2021 Adamas Pharmaceuticals, Inc. | All Rights Reserved. Confidential and Proprietary. Forward looking statements › Statements contained in this presentation regarding matters that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statement ...